Newsletter Subject

A STRONG Buy Stock that Could Skyrocket 🚀

From

elitetrade.club

Email Address

adam@elitetrade.club

Sent On

Wed, Sep 28, 2022 12:12 PM

Email Preheader Text

Biotech is leading today's premarket gainers. Get a full report on all 4 top stocks inside Good Morn

Biotech is leading today's premarket gainers. Get a full report on all 4 top stocks inside [Image](www.elitetrade.club) Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. It's Wednesday, September 28th. Let's get ready to trade! Markets 📈 US benchmarks opened higher on Tuesday, but the S&P 500 and Dow reversed course midday and closed with a 0.2% and 0.4% loss, respectively. The Nasdaq edged out a 0.3% gain, and the small-cap Russell 2K added 0.4%. Today, futures are in the red in what has been a volatile premarket. S&P 500 contracts are currently trading 0.6% lower. Sponsored [A STRONG Buy Stock that Could Skyrocket 🚀]( This tiny company has been trending after announcing a groundbreaking distribution deal with Target! Share prices exploded after the news hit the markets, but experts say this could be just the very beginning of a very profitable run up; EF Hutton, Investing.com, and Yahoo Finance have all issued a "buy" rating on this stock, and the Smart Money is starting to take notice. This ground-floor opportunity could be your ticket to triple-digit gains in the weeks ahead, but the trade is moving very fast. [Get the Full Story on This Up-and-Coming Growth Stock Here]( Premarket Highlights 🔎 - The yield on the 10-year US Treasury bond topped 4% for the first time in over a decade, and it has climbed at its fastest rate in 40 years as investors anticipate more rate hikes ahead. - Bank of England says it will buy bonds with long maturities "on whatever scale is necessary" to restore confidence in the country's bonds and currency. What to Watch Today 👀 Fed Remarks Several key officials from the Federal Reserve, including Chairman Jerome Powell, are expected to speak during today's trading session. Their comments could provoke a reaction in the markets, although whether it will be positive or negative remains to be seen. Powell starts speaking at 10:15a ET, with other Fed leaders speaking through 2:30p, approximately. International 🌍 Asia Hong Kong's Hang Seng Composite sold off for 3.4% overnight, while the Shanghai fell 1.6%. Japan's Nikkei 225 also tumbled 1.5%. Europe Germany's DAX is down 1.4%, and the French CAC 40 is showing a 1.2% loss. The Euro Stoxx 600 is down 1.3%. Major Earnings 💰 Paychex [PAYX] ... AM Cintas [CTAS] ... AM Thor Industries [THO] ... AM QIWI [QIWI] ... AM Cognyte Software [CGNT] ... AM DMARKET Electronic Services [HEPS] ... AM Vail Resorts [MTN] ... PM Jefferies Financial Group [JEF] ... PM Concentrix [CNXC] ... PM The Duckhorn Portfolio [NAPA] ... PM MillerKnoll [MLKN] ... PM Enerpac Tool Group [EPAC] ... PM Economy 🏗 - Trade in goods, advance report [Aug] ... 8:30a - Pending home sales index [Aug] ... 10a Running Hot 🔥 Gainers - Longeveron [LGVN] >> +23.6% - Biodesix Inc [BDSX] >> +43.6% - Nextplat Corp [NXPL] >> +41.6% Decliners - Mind Medicine [MNMD] >> (36.5%) - iBio [IBIO] >> (33.5%) - Nano Labs Ltd ADR [NA] >> (25.8%) Biogen [BIIB] - Last Close: $197.79 New drug data is skyrocketing shares of this mid-cap biotech stock. The company said late Tuesday that the experimental Alzheimer's treatment it co-developed with Eisai Co. met all of its primary and secondary endpoints in a Phase 3 trial. Lecanemab reduced clinical decline on the global cognitive and functional scale compared with placebo by 27% at 18 months. Eisai, Biogen's clinical partner, says it will file for traditional approval in the US, along with marketing applications in Japan and Europe before Mar. 2023. Eisai and Biogen are co-commercializing and co-promoting the product, with Eisai having final decision-making authority. BIIB is today's #1 S&P 500 stock, with an incredible 45.6% premarket gain on active trading volume. My Take: It's not everyday you see a $29 billion company add $13 billion to its market-cap overnight, but an effective Alzheimer's treatment is the biotech industry's Holy Grail. This rally could put BIIB past a key resistance point at $275, so it'll be interesting to see where things go from here. Prothena Corporation [PRTA] - Last Close: $30.93 Prothena is also rallying on the upbeat drug data from Biogen and Eisai. The late-stage clinical biotech firm is moving higher in the premarket without any noteworthy news, and it's likely because Biogen's progress bodes well for Prothena's own Alzheimer's therapy. Prothena currently has several potential Alzheimer's treatment in development, including its PRX012 treatment and a dual Ass-Tau vaccine for the treatment and prevention of the disease. PRTA is one of this morning's top performers with a 61.9% gain on the Biogen news. My Take: I don't have a PhD in chemistry, so I am not sure exactly what the chemical similarities between these drugs are. However, the market clearly seems to think the BIIB news is a good sign for PRTA's similar therapies. Acumen Pharmaceuticals [ABOS] - Last Close: $4.70 Acumen is yet another biotech stock on the move in light of the BIIB news. The specialty boutique biotech firm focuses on clinical-stage therapies for Alzheimer's disease, and it's also getting a boost from the Biogen-Eisai news. Acumen is currently focusing on advancing a target immunotherapy drug candidate ACU193, a monoclonal antibody currently undergoing Phase 1 trials. Sharp-eyed investors are zeroing in on ABOS in the wake of Biogen & Eisai's clinical breakthrough. In fact, ABOS is currently this morning's most active premarket stock. ABOS is also one of the morning's top performers with an 86.5% gain. My Take: Wow, the BIIB news has really sparked a mad dash for Alzheimer's-related biotech stocks. I don't know enough about ABOS's therapy to predict which way this thing will go, but it's unusual to see such strong gains from so many stocks on one company's clinical data. Silo Pharma [SILO] - Last Close: $5.10 Silo Pharma is rebounding after taking sharp losses on Tuesday. The micro-cap biopharma stock tumbled 24.6% in yesterday's session, and the stock has struggled since announcing a 1-for-50 reverse stock split a couple of weeks ago. The reverse split was intended to bring the company's stock into compliance with Nasdaq listing standards, so the company could uplist its shares to the major exchange. Silo has now successfully completed its up-listing to Nasdaq, and its shares are getting a boost on the news. SILO is one of this morning's top stocks with a 44.1% gain. My Take: SILO has gotten beaten down for the past two weeks, but it's showing signs of life today. There could be substantial upside if SILO's recent selloff was overdone, so this could be an excellent entry point for a potential swing trade. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 or [click here]( to sign up now and get our watchlists sent directly to your phone! Or Text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](

Marketing emails from elitetrade.club

View More
Sent On

08/12/2024

Sent On

07/12/2024

Sent On

06/12/2024

Sent On

06/12/2024

Sent On

03/12/2024

Sent On

03/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.